The Scotland-based firm said that it will use the money for the development of its cancer tests and commercialization in new markets.

Last week, readers were most interested in a story about two Medicare administrative contractors delaying the implementation of a policy not to cover certain genetic tests.

Last week, readers were most interested in a story about two Medicare administrative contractors delaying the implementation of a policy not to cover certain genetic tests.

In one, a North Carolina lab allegedly billed for unnecessary urine drug tests, and in the other a Californian women submitted fraudulent claims for respiratory pathogen testing.

The firm reported that its full-year 2024 revenues were up slightly as a rise in the diagnostics business was mostly offset by a decline in life sciences business.

AlterDiag will take full responsibility for the industrialization, regulatory restrictions, and commercialization of the tests.

The firm reported that its full-year 2024 revenues were up slightly as a rise in the diagnostics business was mostly offset by a decline in life sciences business.

The small Baltimore-based lab is preparing for the possibility of additional appeals as years of litigation wind down.